ruxolitinib (ruxolitinib)
Overview of ruxolitinib
ruxolitinib blocks certain enzymes in the body that affect blod cell production,to treat myelofibrosis or polycythemia vera which are bone marrow disorders that affect body`s ability to produce cells
Indication of ruxolitinib
ruxolitinib is primarily indicated in conditions like Myelofibrosis, Polycythemia vera.
Contraindication of ruxolitinib
No data regarding the contra indications of ruxolitinib is available.
Side Effects of ruxolitinib
The signs and symptoms that are produced after the acute overdosage of ruxolitinib include Vomiting, Dizziness, Headache, Thrombocytopenia, Vertigo, Neutropenia.
Precautions of ruxolitinib
Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia. Serious bacterial, mycobacterial, fungal and viral infections have occurred. Delay starting therapy with Jakafi until active serious infections have resolved. Observe patients receiving Jakafi for signs and symptoms of infection and manage promptly. Progressive multifocal leukoencephalopathy (PML) has occurred with ruxolitinib treatment for myelofibrosis. If PML is suspected, stop Jakafi and evaluate. Advise patients about early signs and symptoms of herpes zoster and to seek treatment as early as possible. Following discontinuation of Jakafi, symptoms from myeloproliferative neoplasms may return to pretreatment levels over a period of approximately one week